Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 987-994

  Liu, Zhe Bin ^a   Liu, Guang Yu ^a   Yang, Wen Tao ^a   Di, Gen Hong ^a   Lu, Jin Song ^a   Shen, Kun Wei ^a   Shen, Zhen Zhou ^a   Shao, Zhi Min ^a   Wu, Jiong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast neoplasm; Chinese; Human epidermal growth factor receptor 2; Luminal A; Luminal B; Prognosis; Triple negative phenotype

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GENE PRODUCT; LUMINAL A; LUMINAL B; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHINESE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOBARBITAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 54949144968     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000100     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
2. Lohrisch C and Piccart M: An overview of HER2. Semin Oncol 28: 3-11, 2001.
3. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH and Bernards R: A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
4. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR and Huang AT: Gene expression predictors of breast cancer outcomes. Lancet 361: 1590-1596, 2003.
5. Sotiriou C, Neo SY, McShane LM, Kom EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
6. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO and Botstein D: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217, 1999.
7. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
8. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
9. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
11. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
12. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271, 2006.
13. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
14. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
15. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109: 1721-1728, 2007.
16. Kurebayashi J, Moriya J, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M and Nakashima K: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast DOI 10.1016/j.breast.2007.07.017, 2007.
17. Chu KC, Lamar CA and Freeman HP: Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97: 2853-2860, 2003.
18. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL and Prentice R: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448, 2005.
19. Blackman DJ and Masi CM: Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol 24: 2170-2178, 2006.
20. Braun KL, Fong M, Gotay C, Pagano IS and Chong C: Ethnicity and breast cancer in Hawaii: increased survival but continued disparity. Ethn Dis 15: 453-460, 2005.
21. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
22. Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, Suzuki M, Nakajima T and Miller LS: Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. Proc Natl Acad Sci USA 82: 4803-4807, 1985.
23. Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L and Jackisch C: Estrogen receptor α and β, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep 12: 695-699, 2004.
24. Gouvâa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC and Gobbi H: Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 14: 103-108, 2006.
25. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17: 1983-1987, 1999.
26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
27. Saez RA, McGuire WL and Clark GM: Prognostic factors in breast cancer. Semin Surg Oncol 15: 102-110, 1989.
28. Robertson J: Prognostic and response markers in the management of breast cancer. Cancer Treat Rev 23: S41-S48,1997.
29. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF and Ellis IO: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208: 495-506, 2006.
30. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671, 2004.
31. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK and Kordek R: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69: 478-485, 2005.
32. Gusterson BA, Ross DT, Heath VJ and Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7: 143-148, 2005.
33. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Køchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D and Brown P: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996, 2002.
34. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple-negative early-stage breast cancer. J Clin Oncol 24: 5652-5657, 2006.
35. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB and Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/ neu-overexpressing phenotypes. Hum Pathol 37: 1217-1226, 2006.
36. Ikeda T: Recent prognostic factors for breast cancer. Gan To Kagaku Ryoho 24: 635-643, 1997.
37. Carter CL, Allen C and Henderson DE: Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63: 181-187, 1989.
38. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW and Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340-350, 2005.
39. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W and Buerger H: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82: 1525-1533, 2002.
40. Matos I, Dufloth R, Alvarenga M, Zeferino LC and Schmitt F: p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447: 688-694, 2005.
41. +) phenotype of BRCA1-related breast cancer. Cancer Res 64: 830-835, 2004.